Факторы риска раннего развития септического шока у больных тяжелым COVID-19
Факторы риска раннего развития септического шока у больных тяжелым COVID-19
Глыбочко П.В., Фомин В.В., Моисеев С.В. и др. Факторы риска раннего развития септического шока у больных тяжелым COVID-19. Терапевтический архив. 2020; 92 (11): 17–23. DOI: 10.26442/00403660.2020.11.000780
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Анализ факторов, ассоциированных с ранним развитием септического шока у больных с тяжелым течением COVID-19.
Материалы и методы. В исследование включены данные всех пациентов, проконсультированных до 1 мая 2020 г. на базе Федерального дистанционного консультативного центра анестезиологии и реаниматологии на базе ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет). Критерием септического шока считали снижение артериального давления, требовавшее введения вазопрессорных средств.
Результаты. В исследование включены 1078 пациентов, 611 (56,7%) мужчин и 467 (43,3%) женщин. Средний возраст составил 61,0±13,7 года; 525 (48,7%) заявок на консультацию получены из стационаров Москвы, 159 (14,7%) – Московской области, 394 (36,5%) – лечебных учреждений в 58 регионах Российской Федерации. У 613 (56,9%) больных диагноз SARS-CoV-2-инфекции подтвержден с помощью полимеразной цепной реакции, а в остальных случаях установлен на основании клинической картины и результатов компьютерной томографии органов грудной клетки. Развитие септического шока отмечено у 214 (19,9%) из 1078 больных.
В логистической регрессионной модели риск его развития у пациентов старше 50 лет выше, чем у больных более молодого возраста (отношение шансов 2,34; 95% доверительный интервал 1,53–3,67; р<0,0001). У пациентов с более тяжелым течением SARS-CoV-2 отмечалось увеличение частоты сердечно-сосудистых заболеваний в целом, ишемической болезни сердца, фибрилляции предсердий, сахарного диабета 2-го типа, частота злокачественных опухолей выше. Риск развития септического шока у пациентов с тремя и более сопутствующими заболеваниями оказался выше, чем у пациентов без сопутствующих болезней (отношение шансов 1,76; 95% доверительный интервал 1,76–2,70).
Заключение. Риск развития септического шока у пациентов с острым респираторным дистресс-синдромом, вызванным SARS-CoV-2, выше у пациентов старше 50 лет, страдающих несколькими сопутствующими заболеваниями, хотя тяжелое течение заболевания возможно и у более молодых людей без какой-либо сопутствующей патологии.
Ключевые слова: SARS-CoV-2, COVID-19, острый респираторный дистресс-синдром, септический шок.
Materials and methods. We collected medical records of the intensive care unit patients submitted by the local COVID-19 hospitals across Russia to the Federal Center for the Critical Care at the Sechenov First Moscow State Medical University (Sechenov University). Septic shock in crticially ill patients requiring mechanical ventilation was defined as a need in vasopressors to maintain blood pressure.
Results. We studied 1078 patients with severe COVID-19 who were admitted to the intensive care units for respiratory support. There were 611 males and 467 females. The mean age was 61.0±13.7 years. Five hundred twenty five medical records (48.7%) were received from the Moscow hospitals, 159 (14.7%) from the Moscow region, and 394 (36.5%) from the hospitals located in 58 regions of the Russian Federation. In 613 (56.9%) patients, diagnosis of SARS-CoV-2 infection was confirmed by PCR, and in the other cases it was established on the basis of the clinical picture and the results of the chest CT scan. Septic shock developed in 214 (19.9%) of 1078 patients. In the logistic regression model, the risk of septic shock in patients older than 50 years was higher than in patients of a younger age (OR 2.34; 95% CI 1.53–3.67; p<0.0001). In patients with more severe SARS-CoV-2 infection, there was an increase in the prevalence of cardiovascular diseases, including coronary heart disease and atrial fibrillation, type 2 diabetes and malignant tumors. The risk of septic shock in patients with three or more concomitant diseases was higher than in patients without any concomitant chronic diseases (OR 1.76; 95% CI 1.76–2.70).
Conclusion. The risk of septic shock in patients with acute respiratory distress syndrome induced by SARS-CoV-2 is higher in patients older than 50 years with concomitant diseases, although a severe course of the disease is also possible in younger patients without any concomitant disorders.
Key words: SARS-CoV-2, COVID-19, acute respiratory distress syndrome, septic shock.
Материалы и методы. В исследование включены данные всех пациентов, проконсультированных до 1 мая 2020 г. на базе Федерального дистанционного консультативного центра анестезиологии и реаниматологии на базе ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет). Критерием септического шока считали снижение артериального давления, требовавшее введения вазопрессорных средств.
Результаты. В исследование включены 1078 пациентов, 611 (56,7%) мужчин и 467 (43,3%) женщин. Средний возраст составил 61,0±13,7 года; 525 (48,7%) заявок на консультацию получены из стационаров Москвы, 159 (14,7%) – Московской области, 394 (36,5%) – лечебных учреждений в 58 регионах Российской Федерации. У 613 (56,9%) больных диагноз SARS-CoV-2-инфекции подтвержден с помощью полимеразной цепной реакции, а в остальных случаях установлен на основании клинической картины и результатов компьютерной томографии органов грудной клетки. Развитие септического шока отмечено у 214 (19,9%) из 1078 больных.
В логистической регрессионной модели риск его развития у пациентов старше 50 лет выше, чем у больных более молодого возраста (отношение шансов 2,34; 95% доверительный интервал 1,53–3,67; р<0,0001). У пациентов с более тяжелым течением SARS-CoV-2 отмечалось увеличение частоты сердечно-сосудистых заболеваний в целом, ишемической болезни сердца, фибрилляции предсердий, сахарного диабета 2-го типа, частота злокачественных опухолей выше. Риск развития септического шока у пациентов с тремя и более сопутствующими заболеваниями оказался выше, чем у пациентов без сопутствующих болезней (отношение шансов 1,76; 95% доверительный интервал 1,76–2,70).
Заключение. Риск развития септического шока у пациентов с острым респираторным дистресс-синдромом, вызванным SARS-CoV-2, выше у пациентов старше 50 лет, страдающих несколькими сопутствующими заболеваниями, хотя тяжелое течение заболевания возможно и у более молодых людей без какой-либо сопутствующей патологии.
Ключевые слова: SARS-CoV-2, COVID-19, острый респираторный дистресс-синдром, септический шок.
________________________________________________
Materials and methods. We collected medical records of the intensive care unit patients submitted by the local COVID-19 hospitals across Russia to the Federal Center for the Critical Care at the Sechenov First Moscow State Medical University (Sechenov University). Septic shock in crticially ill patients requiring mechanical ventilation was defined as a need in vasopressors to maintain blood pressure.
Results. We studied 1078 patients with severe COVID-19 who were admitted to the intensive care units for respiratory support. There were 611 males and 467 females. The mean age was 61.0±13.7 years. Five hundred twenty five medical records (48.7%) were received from the Moscow hospitals, 159 (14.7%) from the Moscow region, and 394 (36.5%) from the hospitals located in 58 regions of the Russian Federation. In 613 (56.9%) patients, diagnosis of SARS-CoV-2 infection was confirmed by PCR, and in the other cases it was established on the basis of the clinical picture and the results of the chest CT scan. Septic shock developed in 214 (19.9%) of 1078 patients. In the logistic regression model, the risk of septic shock in patients older than 50 years was higher than in patients of a younger age (OR 2.34; 95% CI 1.53–3.67; p<0.0001). In patients with more severe SARS-CoV-2 infection, there was an increase in the prevalence of cardiovascular diseases, including coronary heart disease and atrial fibrillation, type 2 diabetes and malignant tumors. The risk of septic shock in patients with three or more concomitant diseases was higher than in patients without any concomitant chronic diseases (OR 1.76; 95% CI 1.76–2.70).
Conclusion. The risk of septic shock in patients with acute respiratory distress syndrome induced by SARS-CoV-2 is higher in patients older than 50 years with concomitant diseases, although a severe course of the disease is also possible in younger patients without any concomitant disorders.
Key words: SARS-CoV-2, COVID-19, acute respiratory distress syndrome, septic shock.
Список литературы
1. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. doi: 10.1001/jama.2020.2648
2. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020. doi: 10.1002/art.41285
3. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (In Russ.)]. doi: 10.14412/1995-4484-2020-123-132
4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/s0140-6736(20)30628-0
5. Wang D, Hu B, Hu C, et al. Clinical сharacteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585
6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;58(4):713-4. doi: 10.1016/j.jemermed.2020.04.007
7. Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. Lancet Glob Health. 2020;8(5):e641-2.
8. Глыбочко П.В., Фомин В.В., Авдеев С.Н. и др. Клиническая характеристика 1007 больных тяжелой SARS-CoV-2 пневмонией, нуждавшихся в респираторной поддержке. Клин. фармакология и терапия. 2020;29(2):21-9 [Glybochko PV, Fomin VV, Avdeev SN, et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020;29(2):21-9 (In Russ.)]. doi: 10.32756/0869-5490-2020-2-21-29
9. Ren D, Ren R, Yao R-I, et al. Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China. Intensive Care Med. 2020;46:1630-3. doi: 10.1007/s00134-020-06084-5
10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. doi: 10.1001/jama.2016.0287
11. Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. 2018;9:2147. doi: 10.3389/fimmu.2018.02147
12. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517-20. doi: 10.1016/S0140-6736(20)30920-X
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3
14. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 Patients. AJR Am J Roentgenol. 2020; p. 1-7. doi: 10.2214/AJR.20.23034
15. Drucker DJ. Coronavirus infections and type 2 diabetes – shared pathways with therapeutic implications. Endocr Rev. 2020;41(3). pii: bnaa011. doi: 10.1210/endrev/bnaa011
16. Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-6. doi: 10.15585/mmwr.mm6913e2
17. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966
18. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. pii: ciaa415. doi: 1093/cid/ciaa415
19. Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11 [Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. Cardiovascular Therapy and Prevention. 2014;13(6):4-11 (In Russ.)].
20. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020. doi: 10.1136/jclinpath-2020-206658
21. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;82:1653-9. doi: 10.1056/nejmc2013707
22. Moiseev S, Avdeev S, Brovko M, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217676
23. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217460
24. Toniati P, Piva S, Cattalini M, et al; Brescia International Research and Training HUB (BIRTH). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi: 10.1016/j.autrev.2020.102568
25. Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;S0163-4453(20)30228-0. doi: 10.1016/j.jinf.2020.04.017
26. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 от 28.04.2020. https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COV...
27. Moiseev S, Avdeev S, Brovko M, et al. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Ann Rheum Dis. 2020. pii: annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570
28. Geleris J, Sun Y, Platt J, et al. Obesrvational study of hydroxychloroquine in hospitalized patients with COVID-19. NEJM. 2020. doi: 10.1056/ NEJMoa2012410
29. Moiseev S, Avdeev S, Brovko M, et al. Cancer in intensive care unit patients with COVID-19. J Infection. 2020. doi: 10.1016/j.jinf.2020.05.053
30. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020. doi: 10.1111/all.14420
2. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020. doi: 10.1002/art.41285
3. Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (In Russ.) doi: 10.14412/1995-4484-2020-123-132
4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/s0140-6736(20)30628-0
5. Wang D, Hu B, Hu C, et al. Clinical сharacteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585
6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;58(4):713-4. doi: 10.1016/j.jemermed.2020.04.007
7. Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. Lancet Glob Health. 2020;8(5):e641-2.
8. Glybochko PV, Fomin VV, Avdeev SN, et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020;29(2):21-9 (In Russ.) doi: 10.32756/0869-5490-2020-2-21-29
9. Ren D, Ren R, Yao R-I, et al. Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China. Intensive Care Med. 2020;46:1630-3. doi: 10.1007/s00134-020-06084-5
10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. doi: 10.1001/jama.2016.0287
11. Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. 2018;9:2147. doi: 10.3389/fimmu.2018.02147
12. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517-20. doi: 10.1016/S0140-6736(20)30920-X
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3
14. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 Patients. AJR Am J Roentgenol. 2020; p. 1-7. doi: 10.2214/AJR.20.23034
15. Drucker DJ. Coronavirus infections and type 2 diabetes – shared pathways with therapeutic implications. Endocr Rev. 2020;41(3). pii: bnaa011. doi: 10.1210/endrev/bnaa011
16. Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-6. doi: 10.15585/mmwr.mm6913e2
17. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966
18. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. pii: ciaa415. doi: 1093/cid/ciaa415
19. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. Cardiovascular Therapy and Prevention. 2014;13(6):4-11 (In Russ.)
20. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020. doi: 10.1136/jclinpath-2020-206658
21. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;82:1653-9. doi: 10.1056/nejmc2013707
22. Moiseev S, Avdeev S, Brovko M, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217676
23. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217460
24. Toniati P, Piva S, Cattalini M, et al; Brescia International Research and Training HUB (BIRTH). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi: 10.1016/j.autrev.2020.102568
25. Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;S0163-4453(20)30228-0. doi: 10.1016/j.jinf.2020.04.017
26. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 от 28.04.2020. https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COV...
27. Moiseev S, Avdeev S, Brovko M, et al. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Ann Rheum Dis. 2020. pii: annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570
28. Geleris J, Sun Y, Platt J, et al. Obesrvational study of hydroxychloroquine in hospitalized patients with COVID-19. NEJM. 2020. doi: 10.1056/ NEJMoa2012410
29. Moiseev S, Avdeev S, Brovko M, et al. Cancer in intensive care unit patients with COVID-19. J Infection. 2020. doi: 10.1016/j.jinf.2020.05.053
30. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020. doi: 10.1111/all.14420
2. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020. doi: 10.1002/art.41285
3. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (In Russ.)]. doi: 10.14412/1995-4484-2020-123-132
4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/s0140-6736(20)30628-0
5. Wang D, Hu B, Hu C, et al. Clinical сharacteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585
6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;58(4):713-4. doi: 10.1016/j.jemermed.2020.04.007
7. Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. Lancet Glob Health. 2020;8(5):e641-2.
8. Глыбочко П.В., Фомин В.В., Авдеев С.Н. и др. Клиническая характеристика 1007 больных тяжелой SARS-CoV-2 пневмонией, нуждавшихся в респираторной поддержке. Клин. фармакология и терапия. 2020;29(2):21-9 [Glybochko PV, Fomin VV, Avdeev SN, et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020;29(2):21-9 (In Russ.)]. doi: 10.32756/0869-5490-2020-2-21-29
9. Ren D, Ren R, Yao R-I, et al. Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China. Intensive Care Med. 2020;46:1630-3. doi: 10.1007/s00134-020-06084-5
10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. doi: 10.1001/jama.2016.0287
11. Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. 2018;9:2147. doi: 10.3389/fimmu.2018.02147
12. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517-20. doi: 10.1016/S0140-6736(20)30920-X
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3
14. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 Patients. AJR Am J Roentgenol. 2020; p. 1-7. doi: 10.2214/AJR.20.23034
15. Drucker DJ. Coronavirus infections and type 2 diabetes – shared pathways with therapeutic implications. Endocr Rev. 2020;41(3). pii: bnaa011. doi: 10.1210/endrev/bnaa011
16. Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-6. doi: 10.15585/mmwr.mm6913e2
17. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966
18. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. pii: ciaa415. doi: 1093/cid/ciaa415
19. Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11 [Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. Cardiovascular Therapy and Prevention. 2014;13(6):4-11 (In Russ.)].
20. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020. doi: 10.1136/jclinpath-2020-206658
21. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;82:1653-9. doi: 10.1056/nejmc2013707
22. Moiseev S, Avdeev S, Brovko M, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217676
23. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217460
24. Toniati P, Piva S, Cattalini M, et al; Brescia International Research and Training HUB (BIRTH). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi: 10.1016/j.autrev.2020.102568
25. Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;S0163-4453(20)30228-0. doi: 10.1016/j.jinf.2020.04.017
26. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 от 28.04.2020. https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COV...
27. Moiseev S, Avdeev S, Brovko M, et al. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Ann Rheum Dis. 2020. pii: annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570
28. Geleris J, Sun Y, Platt J, et al. Obesrvational study of hydroxychloroquine in hospitalized patients with COVID-19. NEJM. 2020. doi: 10.1056/ NEJMoa2012410
29. Moiseev S, Avdeev S, Brovko M, et al. Cancer in intensive care unit patients with COVID-19. J Infection. 2020. doi: 10.1016/j.jinf.2020.05.053
30. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020. doi: 10.1111/all.14420
________________________________________________
2. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020. doi: 10.1002/art.41285
3. Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (In Russ.) doi: 10.14412/1995-4484-2020-123-132
4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/s0140-6736(20)30628-0
5. Wang D, Hu B, Hu C, et al. Clinical сharacteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585
6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;58(4):713-4. doi: 10.1016/j.jemermed.2020.04.007
7. Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. Lancet Glob Health. 2020;8(5):e641-2.
8. Glybochko PV, Fomin VV, Avdeev SN, et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020;29(2):21-9 (In Russ.) doi: 10.32756/0869-5490-2020-2-21-29
9. Ren D, Ren R, Yao R-I, et al. Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China. Intensive Care Med. 2020;46:1630-3. doi: 10.1007/s00134-020-06084-5
10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. doi: 10.1001/jama.2016.0287
11. Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. 2018;9:2147. doi: 10.3389/fimmu.2018.02147
12. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517-20. doi: 10.1016/S0140-6736(20)30920-X
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3
14. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 Patients. AJR Am J Roentgenol. 2020; p. 1-7. doi: 10.2214/AJR.20.23034
15. Drucker DJ. Coronavirus infections and type 2 diabetes – shared pathways with therapeutic implications. Endocr Rev. 2020;41(3). pii: bnaa011. doi: 10.1210/endrev/bnaa011
16. Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-6. doi: 10.15585/mmwr.mm6913e2
17. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966
18. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. pii: ciaa415. doi: 1093/cid/ciaa415
19. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. Cardiovascular Therapy and Prevention. 2014;13(6):4-11 (In Russ.)
20. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020. doi: 10.1136/jclinpath-2020-206658
21. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;82:1653-9. doi: 10.1056/nejmc2013707
22. Moiseev S, Avdeev S, Brovko M, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217676
23. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217460
24. Toniati P, Piva S, Cattalini M, et al; Brescia International Research and Training HUB (BIRTH). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi: 10.1016/j.autrev.2020.102568
25. Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;S0163-4453(20)30228-0. doi: 10.1016/j.jinf.2020.04.017
26. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 от 28.04.2020. https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COV...
27. Moiseev S, Avdeev S, Brovko M, et al. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Ann Rheum Dis. 2020. pii: annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570
28. Geleris J, Sun Y, Platt J, et al. Obesrvational study of hydroxychloroquine in hospitalized patients with COVID-19. NEJM. 2020. doi: 10.1056/ NEJMoa2012410
29. Moiseev S, Avdeev S, Brovko M, et al. Cancer in intensive care unit patients with COVID-19. J Infection. 2020. doi: 10.1016/j.jinf.2020.05.053
30. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020. doi: 10.1111/all.14420
Авторы
П.В. Глыбочко, В.В. Фомин, С.В. Моисеев, С.Н. Авдеев, А.Г. Яворовский, М.Ю. Бровко, К.Т. Умбетова, В.А. Алиев, Е.Л. Буланова, И.Б. Бондаренко, О.С. Волкова, В.В. Гайнитдинова, Т.Ю. Гнеушева, К.В. Дубровин, В.А. Капустина, В.В. Краева, З.М. Мержоева, Г.С. Нуралиева, П.В. Ногтев, В.В. Панасюк, М.Е. Политов, А.М. Попов, Е.Н. Попова, Н.А. Распопина, В.В. Роюк, Ю.Д. Сорокин, Н.В. Трушенко, Е.Ю. Халикова, Н.А. Царева, С.Ю. Чикина, Н.В. Чичкова, Л.А. Акулкина, Н.М. Буланов, Л.А. Ермолова, А.С.
Зыкова, А.А. Китбалян, А.С. Моисеев, П.П. Потапов, Е.А. Тао, В.И. Шоломова, А.А. Щепалина, А.А. Яковлева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Зыкова, А.А. Китбалян, А.С. Моисеев, П.П. Потапов, Е.А. Тао, В.И. Шоломова, А.А. Щепалина, А.А. Яковлева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.